查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827986

活細胞封裝市場（按應用、技術、材料、最終用戶和細胞類型）—2025-2032 年全球預測

Live Cell Encapsulation Market by Application, Technology, Material, End User, Cell Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年活細胞封裝市場規模將成長至 4.6656 億美元，複合年成長率為 4.58%。

主要市場統計數據
基準年2024年 3.2589億美元
預計2025年 3.4117億美元
預測年份：2032年 4.6656億美元
複合年成長率（%） 4.58%

簡要介紹技術、應用和臨床需求，為活細胞封裝的突破奠定基礎

活細胞封裝技術是材料科學、細胞治療和醫療設備工程的交叉領域，為保護、維持和控制治療細胞的生物活性提供了一種突破性的方法。從根本上講，封裝技術將活細胞置於半透性屏障內，保護細胞免受免疫排斥和機械應力的影響，同時允許營養物質和廢物的交換。這項技術前提已促進了腫瘤學、代謝疾病、藥物傳遞和組織修復等領域的應用，將這一概念從實驗室示範推進到轉化醫學發展。

近年來，聚合物化學、微加工技術和細胞獲取技術的進步，拓展了封裝細胞療法的功能範圍和轉化可行性。監管機構對製劑的期望日益明確，臨床項目也從概念驗證轉向長期安全性和有效性評估。因此，產業相關人員正在探索多種商業化途徑，從局部組織工程構建體到提供內分泌和免疫調節功能的植入式裝置。

鑑於這些動態，清晰的策略對於相關人員至關重要。開發商必須同時優先考慮材料相容性、可製造性和監管策略，而投資者和合作夥伴則必須根據技術差異評估臨床風險。本介紹概述了將資源集中在封裝上的技術和商業性原理，為後續章節中更深入地討論市場促進因素、細分市場和營運考慮奠定了基礎。

透過科學進步、監管變化和跨學科合作，識別重塑活細胞封裝的變革性轉變

一系列相互依存的變革正在重新定義機會和風險，活細胞封裝的模式正在迅速改變。封裝材料和微加工技術的科學進步正在提高耐用性和細胞活力，使其能夠長期發揮作用，並擴大潛在適應症。同時，細胞來源的改進，尤其是可再生細胞衍生產品和細胞株工程的進步，正在降低差異性，並擴大可封裝的治療有效載荷的範圍。

同時，法律規範也在不斷發展，以適應組合產品和生物材料-器械介面，這加速了開發商和監管機構之間的對話，並提高了臨床前安全數據、生產控制和清晰的效益-風險描述的重要性。在商業性方面，付款人和醫療保健系統要求提供持續臨床效益和成本效益的證據，並將開發重點轉向能夠展現有意義的患者療效和健康經濟價值的終點。

這些技術、監管和商業性變革，加上供應鏈物流、品管系統和數位化製造的進步，使得許多開發商能夠實現先前遙不可及的規模擴張。因此，該行業正變得越來越分化：一方面是能夠自主管理電池採購、封裝和製造的垂直整合公司，另一方面是專注於材料、設備以及合約開發和製造服務的專業供應商。這種轉變有利於那些能夠將技術差異化與嚴謹的監管和商業化策略結合的組織。

評估 2025 年美國關稅對活細胞封裝供應鏈、零件成本和策略採購的累積影響

2025年徵收關稅和貿易政策轉變將對活細胞封裝生態系統產生累積累積，改變進口零件的經濟性，推動採購變革，並凸顯供應鏈的脆弱性。許多封裝系統依賴全球採購的專用聚合物、試劑、醫療器材和精密儀器。對投入品徵收關稅可能會增加到岸成本，從而壓縮製造商、合約供應商和最終用戶的計劃預算和決策點。

為了應對這項挑戰，企業正在加快關鍵供應鏈的本地化進程，例如篩選合格的國內供應商、跨地區雙重採購原料，或鼓勵上游供應商將生產基地設在更靠近製造地的地方。這一趨勢會影響前置作業時間、庫存策略以及擴大規模所需的資本配置。一些開發商正在協商長期供應協議並建立聯合生產夥伴關係關係，以減輕關稅的影響並保持其臨床項目的連續性。

除了成本影響之外，關稅還促使企業重新評估產品設計和材料清單，包括轉向貿易摩擦較少的材料和零件。戰略應對措施還包括在法律允許的情況下利用貿易優惠計劃、保稅倉庫和關稅工程等關稅緩解機制。總而言之，2025年的關稅格局強調了靈活的籌資策略和早期供應鏈整合在封裝細胞療法商業化計畫中的重要性。

關鍵細分洞察闡明了跨應用、技術、材料、最終用戶和細胞類型的價值路徑，有助於策略決策

細緻的細分框架清楚地闡明了在活細胞封裝領域，技術投入和商業性重點將在哪些領域產生最高回報。按應用領域分類，該領域包括細胞療法、糖尿病管理、藥物傳輸和組織工程。在細胞療法領域，開發人員專注於癌症免疫療法和再生療法；而在糖尿病管理計畫中，他們區分胰島素分泌細胞傳遞和胰島細胞移植。藥物輸送分為控制釋放和標靶輸送，而組織工程涵蓋骨、心臟和軟骨組織工程。這些不同的應用對設備幾何形狀、免疫隔離性能和臨床終點提出了不同的要求。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合微流體液滴生成技術，實現可擴展的細胞封裝，增強均勻性和活力
  • 富含 RGD 胜肽的藻酸鹽基水凝膠調變器的出現改善了封裝細胞的分化和功能。
  • 採用 3D 生物列印技術製造可客製化的含細胞膠囊，用於靶向藥物傳輸和組織工程
  • 引入免疫逃脫聚合物塗層來延長封裝胰島細胞的體內存活時間，用於治療糖尿病
  • 開發感測器整合封裝系統，可以即時監測細胞微環境和代謝狀態
  • 採用結合幹細胞和生長因子奈米粒子的共封裝策略可提供協同再生效應。
  • 促進標準化品管檢測法規，確保封裝細胞產品批次間性能的一致性
  • 人們對無冷凍保護劑封裝工作流程的興趣日益濃厚，以提高細胞療法解凍後的活力
  • 開發可擴展的生物反應器平台，用於高通量生產攜帶治療細胞的微膠囊
  • 將人工智慧主導的流程最佳化整合到您的封裝工作流程中，以提高可重複性和擴充性。

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第8章活細胞封裝市場（依應用）

  • 細胞療法
    • 癌症免疫治療
    • 再生療法
  • 糖尿病管理
    • 輸送至胰島素產生細胞
    • 胰島細胞移植
  • 藥物輸送
    • 控釋
    • 靶向藥物輸送
  • 組織工程
    • 骨組織工程
    • 心臟組織工程
    • 軟骨組織工程

9. 活細胞封裝市場（依技術）

  • 大分子膠囊化
    • 中空纖維裝置
    • 水凝膠片
  • 微膠囊化
    • 乳化技術
    • 擠壓成型技術
    • 噴霧乾燥

第 10 章活細胞封裝市場（依材料）

  • 藻酸鹽
    • 高膠凝海藻酸鹽
    • 低膠凝海藻酸鹽
  • 幾丁聚醣
    • 交聯幾丁聚醣
    • 去乙醯幾丁聚醣
  • 膠原蛋白
  • 合成聚合物

第 11 章。活細胞封裝市場（依最終用戶）

  • 生技公司
  • 醫院和診所
  • 製藥公司
  • 研究機構

第 12 章活細胞封裝市場（依細胞類型）

  • 胰島細胞
    • 供體胰島細胞
    • 幹細胞衍生的胰島細胞
  • 益生菌
    • 雙歧桿菌
    • 乳酸菌
  • 幹細胞
    • 誘導性多功能細胞
    • 間質幹細胞

第13章活細胞封裝市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章活細胞封裝市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。活細胞封裝市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • AUSTRIANOVA
    • Merck KGaA
    • Sphere Fluidics Ltd.
    • ViaCyte, Inc.
    • Blacktrace Holdings Ltd.（Dolomite Microfluidics）
    • BIO INX
    • Living Cell Technologies Ltd.
    • Sigilon Therapeutics, Inc.
    • Isogen
    • Diatranz Otsuka Ltd.
    • Sernova Corporation
    • Atelerix Ltd.
    • Neurotech Pharmaceuticals
    • Kadimastem
    • BUCHI Labortechnik AG
    • Fluigent
    • Encapsys LLC
    • MiKroCaps
    • Reed Pacific Pty Limited
    • Lycored
Product Code: MRR-437517DB6D5D

The Live Cell Encapsulation Market is projected to grow by USD 466.56 million at a CAGR of 4.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 325.89 million
Estimated Year [2025] USD 341.17 million
Forecast Year [2032] USD 466.56 million
CAGR (%) 4.58%

Setting the stage for live cell encapsulation breakthroughs with a concise introduction to technologies, applications, and clinical imperatives

Live cell encapsulation stands at the intersection of materials science, cellular therapy, and medical device engineering, offering a transformative means to protect, sustain, and control the biological activity of therapeutic cells. At a basic level, encapsulation technologies enclose living cells within a semi-permeable barrier that permits nutrient and waste exchange while shielding cells from immune rejection or mechanical stress. This technical premise has catalyzed applications across oncology, metabolic disease, drug delivery, and tissue repair, transitioning the concept from laboratory demonstration to translational development.

Over recent years, advances in polymer chemistry, microfabrication, and cell sourcing have converged to expand both the functional scope and translational feasibility of encapsulated cell therapies. Regulatory agencies are increasingly clarifying expectations for combination products, and clinical programs are moving beyond proof-of-concept to longer-term safety and efficacy evaluation. Consequently, industry participants are progressing along multiple commercialization pathways-ranging from localized tissue engineering constructs to implantable devices delivering endocrine or immunomodulatory functions.

Given these dynamics, strategic clarity is essential for stakeholders. Developers must prioritize material compatibility, manufacturability, and regulatory strategy concurrently, while investors and partners evaluate clinical risk against technical differentiation. This introduction frames the technical and commercial rationale for focusing resources on encapsulation, and sets the stage for deeper discussion of market drivers, segmentation, and operational considerations contained in the subsequent sections.

Identifying transformative shifts reshaping live cell encapsulation driven by scientific advances, regulatory change, and cross-disciplinary collaboration

The live cell encapsulation landscape is changing rapidly due to a set of interdependent shifts that together redefine opportunity and risk. Scientific advances in encapsulation materials and microfabrication have increased durability and cell viability, enabling longer-term functionality and expanding potential indications. At the same time, improvements in cell sourcing-particularly renewable stem cell-derived products and improved cell-line engineering-reduce variability and expand the range of therapeutic payloads that can be encapsulated.

Concurrently, regulatory frameworks are evolving to address combination products and biomaterial-device interfaces, prompting earlier dialog between developers and regulators and raising the premium on preclinical safety data, manufacturing controls, and clear benefit-risk articulation. On the commercial side, payers and health systems demand evidence of durable clinical benefit and cost-effectiveness, reshaping development priorities toward endpoints that demonstrate meaningful patient outcomes and health economic value.

These technical, regulatory, and commercial shifts are amplified by advances in supply chain logistics, quality management systems, and digital manufacturing controls, which together enable scale-up pathways previously out of reach for many developers. As a result, the industry is seeing a stratification between vertically integrated players that can manage cell sourcing, encapsulation, and manufacturing in-house, and specialized suppliers that focus on materials, devices, or contract development and manufacturing services. This transformation favors organizations that combine technical differentiation with disciplined regulatory and commercialization strategies.

Assessing the cumulative impact of United States tariffs in 2025 on supply chains, component costs, and strategic sourcing for live cell encapsulation

The imposition of tariffs and trade policy shifts in 2025 has had a cumulative effect on the live cell encapsulation ecosystem by altering the economics of imported components, spurring sourcing changes, and highlighting supply chain vulnerabilities. Many encapsulation systems depend on specialized polymers, reagents, medical-grade equipment, and precision devices sourced globally. Tariffs on inputs can increase landed cost, which in turn pressures project budgets and decision points for manufacturers, contract providers, and end users.

In response, organizations have accelerated efforts to localize critical supply chains, either by qualifying domestic suppliers, dual sourcing materials across regions, or incentivizing upstream vendors to establish production close to manufacturing hubs. This trend has implications for lead times, inventory strategies, and capital allocation for scale-up; it also influences where clinical and manufacturing activities are concentrated. Some developers have negotiated longer-term supply agreements and engaged in collaborative manufacturing partnerships to mitigate tariff exposure and maintain continuity for clinical programs.

Beyond cost impacts, tariffs have encouraged careful re-evaluation of product design and bill of materials, including a shift toward materials and components that can be sourced with fewer trade frictions. Strategic responses also include leveraging tariff mitigation mechanisms such as trade preference programs, bonded warehousing, or tariff engineering where legally appropriate. In sum, the 2025 tariff landscape has reinforced the importance of resilient sourcing strategies and early supply chain integration in commercialization planning for encapsulated cell therapies.

Key segmentation insights that clarify value pathways across application, technology, material, end user, and cell type dimensions for strategic decision-making

A nuanced segmentation framework clarifies where technical effort and commercial focus will yield the highest returns in live cell encapsulation. Based on application, the field encompasses Cell Therapy, Diabetes Management, Drug Delivery, and Tissue Engineering; within Cell Therapy developers concentrate on Cancer Immunotherapy and Regenerative Therapy, while Diabetes Management programs differentiate between Insulin-Producing Cell Delivery and Islet Cell Transplantation. Drug Delivery efforts split between Controlled Release and Targeted Drug Delivery approaches, and Tissue Engineering initiatives target Bone Tissue Engineering, Cardiac Tissue Engineering, and Cartilage Tissue Engineering. These application distinctions drive divergent requirements for device geometry, immunoisolation performance, and clinical endpoints.

Based on technology, encapsulation solutions fall into Macroencapsulation and Microencapsulation. Macroencapsulation developers use approaches such as Hollow Fiber Devices and Hydrogel Sheets, prioritizing implantability and retrievability, while Microencapsulation leverages techniques like Emulsion Technique, Extrusion Technique, and Spray Drying to optimize mass transfer and cell packing density. Material selection is another critical axis: Alginate, Chitosan, Collagen, and Synthetic Polymer each present distinctive biocompatibility and manufacturing profiles, with Alginate variants categorized as High Gelation and Low Gelation and Chitosan available as Crosslinked and Deacetylated forms.

End user segmentation highlights the divergent needs of Biotechnology Companies, Hospitals & Clinics, Pharmaceutical Companies, and Research Institutes, influencing support services, regulatory expectations, and purchasing behaviors. Finally, cell type matters: Islet Cells are differentiated into Donor Islet Cells and Stem Cell Derived Islet Cells; Probiotic Bacteria include Bifidobacterium and Lactobacillus; Stem Cells break down into Induced Pluripotent Stem Cells and Mesenchymal Stem Cells. Together, these segmentation dimensions emphasize that commercial strategy must align material science, encapsulation technique, and clinical pathway to the chosen therapeutic application.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption and commercialization

Regional dynamics shape adoption, regulatory strategy, and supply chain design for live cell encapsulation technologies. In the Americas, markets are characterized by strong venture capital activity, advanced clinical trial ecosystems, and a regulatory environment that emphasizes early sponsor-regulator interaction; this region often serves as a proving ground for clinical evidence and reimbursement models. Europe, Middle East & Africa presents a mosaic of regulatory regimes and health system structures, where alignment with regional regulatory bodies and payer evidence requirements is essential to broaden access across diverse markets. Asia-Pacific shows rapid investment in domestic manufacturing capacity, an expanding base of clinical centres, and government-led initiatives to foster biotech innovation, which together accelerate local development and commercial pathways.

These regional distinctions matter for market entry timing, partner selection, and manufacturing footprint. For example, a development program may choose to validate clinical endpoints and build health economic models in the Americas before pursuing broader regulatory harmonization in Europe, Middle East & Africa, while simultaneously engaging manufacturing partners in Asia-Pacific to reduce cost and shorten lead times. Trade policy, intellectual property frameworks, and public funding priorities vary by region, and successful players synchronize clinical development, supply chain resilience, and commercial launch sequencing to exploit regional strengths. In short, a deliberate regional strategy that leverages complementary advantages across the Americas, Europe, Middle East & Africa, and Asia-Pacific will materially improve scalability and access.

Profiles of leading companies, competitive positioning, and strategic moves shaping product development, partnerships, and commercialization in the live cell encapsulation arena

Company strategies in live cell encapsulation reveal a split between vertically integrated developers and specialized technology providers. Leading innovators invest in proprietary materials, device architectures, and process controls, positioning themselves to capture downstream value through product differentiation and integrated manufacturing. At the same time, a cohort of suppliers focuses on enabling components-high-purity polymers, encapsulation machinery, and contract development and manufacturing services-creating an ecosystem that reduces barriers to entry for clinical-stage developers.

Partnerships and collaborations are a commonplace strategic play. Biotech firms often enter co-development agreements with materials specialists or device manufacturers to accelerate translational timelines and de-risk technical challenges. Meanwhile, contract organizations are expanding capabilities to support aseptic processing, quality systems, and scale-up for combination product manufacturing. Competitive positioning is also shaped by intellectual property around encapsulation chemistries and microfabrication methods, and companies with defensible IP portfolios can secure advantageous licensing arrangements or investment.

Mergers and strategic alliances continue to consolidate capabilities, particularly where a partner can offer complementary strengths such as clinical development expertise, regulatory experience, or commercial distribution. For decision-makers, the landscape rewards clarity about where to invest internally versus where to partner, and encourages an early focus on manufacturability, regulatory alignment, and demonstrable clinical benefit to sustain competitive advantage.

Actionable recommendations for industry leaders to accelerate innovation, de-risk supply chains, and optimize clinical translation pathways in live cell encapsulation

Industry leaders should prioritize a set of actionable initiatives that reduce technical risk, strengthen supply chains, and accelerate clinical translation. First, diversify supplier relationships for critical materials and components while qualifying alternate sources and creating contingency inventory strategies to buffer against geopolitical and trade disruptions. Second, invest in material science efforts aimed at improving biocompatibility and mechanical stability to lengthen device lifetimes and reduce immune responses, thereby improving clinical outcomes and payer receptivity.

Third, engage regulators early with robust preclinical packages and clear manufacturing controls to shorten approval cycles and de-risk pivotal studies. Simultaneously, design clinical programs with endpoints that address patient-centered outcomes and health economic measures to facilitate reimbursement discussions. Fourth, pursue modular manufacturing strategies and digital quality systems to scale production efficiently and maintain traceability across cell-based processes. Fifth, build strategic partnerships with contract manufacturers and clinical trial networks to accelerate enrollment and reduce the time from bench to bedside.

Finally, adopt a proactive IP and commercialization playbook: protect core material and fabrication innovations while licensing or partnering where complementary capabilities exist. Together, these steps create a roadmap for organizations seeking to translate encapsulation innovations into durable products that satisfy regulators, payers, and clinicians alike.

Research methodology that underpins the analysis including data triangulation, stakeholder interviews, and validation protocols for credible live cell encapsulation insights

The research underpinning this analysis employed a multi-method approach combining qualitative and quantitative validation to ensure robustness and relevance. Primary research included structured interviews with senior executives, R&D leaders, regulatory experts, contract manufacturers, and clinical investigators to capture first-hand perspectives on technical barriers, commercialization challenges, and strategic priorities. Secondary sources comprised peer-reviewed literature, patent filings, clinical trial registries, regulatory guidance documents, and supplier catalogs to map technological evolution and identify enabling materials and processes.

Data triangulation was used to corroborate findings across independent sources, and a synthesis layer reconciled clinical, technical, and commercial inputs into actionable insights. The methodology also incorporated supply chain mapping to identify chokepoints and geographic dependencies, and a regulatory heatmap to align development pathways with region-specific requirements. Throughout the process, validation workshops with external experts refined interpretations and ensured practical applicability for decision-makers.

Limitations of the research are acknowledged, including the evolving nature of clinical data and the potential for rapid innovation to shift competitive dynamics. Nonetheless, the methodology emphasizes transparency, stakeholder validation, and reproducibility to provide a credible foundation for strategic decisions in live cell encapsulation.

Concluding synthesis that ties scientific, commercial, and regulatory threads into a coherent outlook for stakeholders engaged in live cell encapsulation

The synthesis presented in this report emphasizes that progress in live cell encapsulation is both technological and organizational. Technically, advances in materials, microfabrication, and cell sourcing are reducing historical barriers to durability and biocompatibility, enabling longer-term therapeutic effects. Organizationally, regulatory evolution, payer scrutiny, and supply chain reconfiguration are shaping which programs advance and which must pivot or consolidate. These dual forces determine the practical pathway to commercialization for encapsulated cell therapies.

Looking across segmentation, technology choices must be matched to application-specific clinical objectives and end-user needs, while regional strategies must balance clinical validation hubs with manufacturing pragmatism. Firms that align product design, material selection, and manufacturable processes with a clear regulatory and reimbursement plan are most likely to achieve sustainable clinical and commercial success. Moreover, the 2025 trade dynamics underscore the value of resilient sourcing and adaptive cost management in maintaining program continuity.

In conclusion, stakeholders should pursue disciplined technical validation, early regulatory engagement, and strategic partnerships to translate encapsulation innovations into therapies that demonstrate durable patient benefit. The path forward rewards integrated approaches that connect scientific differentiation with operational excellence and clear commercial value propositions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of microfluidic droplet generation techniques for scalable cell encapsulation to enhance uniformity and viability
  • 5.2. Emergence of alginate-based hydrogel modulators enriched with RGD peptides to improve cell differentiation and functionality in encapsulation
  • 5.3. Adoption of 3D bioprinting methods to fabricate customizable cell-laden capsules for targeted drug delivery and tissue engineering
  • 5.4. Implementation of immune-evasive polymer coatings to extend in vivo survival of encapsulated islet cells in diabetes therapy
  • 5.5. Development of sensor-integrated encapsulation systems enabling real-time monitoring of cell microenvironment and metabolic status
  • 5.6. Use of co-encapsulation strategies combining stem cells with growth factor-loaded nanoparticles for synergistic regenerative outcomes
  • 5.7. Regulatory momentum around standardized quality control assays for ensuring consistent batch-to-batch performance of encapsulated cell products
  • 5.8. Rising interest in cryoprotectant-free encapsulation workflows to improve post-thaw viability of cell therapies
  • 5.9. Development of scalable bioreactor platforms for high-throughput production of microcapsules carrying therapeutic cells
  • 5.10. Integration of artificial intelligence-driven process optimization in encapsulation workflows for enhanced reproducibility and scalability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Live Cell Encapsulation Market, by Application

  • 8.1. Cell Therapy
    • 8.1.1. Cancer Immunotherapy
    • 8.1.2. Regenerative Therapy
  • 8.2. Diabetes Management
    • 8.2.1. Insulin-Producing Cell Delivery
    • 8.2.2. Islet Cell Transplantation
  • 8.3. Drug Delivery
    • 8.3.1. Controlled Release
    • 8.3.2. Targeted Drug Delivery
  • 8.4. Tissue Engineering
    • 8.4.1. Bone Tissue Engineering
    • 8.4.2. Cardiac Tissue Engineering
    • 8.4.3. Cartilage Tissue Engineering

9. Live Cell Encapsulation Market, by Technology

  • 9.1. Macroencapsulation
    • 9.1.1. Hollow Fiber Devices
    • 9.1.2. Hydrogel Sheets
  • 9.2. Microencapsulation
    • 9.2.1. Emulsion Technique
    • 9.2.2. Extrusion Technique
    • 9.2.3. Spray Drying

10. Live Cell Encapsulation Market, by Material

  • 10.1. Alginate
    • 10.1.1. High Gelation Alginate
    • 10.1.2. Low Gelation Alginate
  • 10.2. Chitosan
    • 10.2.1. Crosslinked Chitosan
    • 10.2.2. Deacetylated Chitosan
  • 10.3. Collagen
  • 10.4. Synthetic Polymer

11. Live Cell Encapsulation Market, by End User

  • 11.1. Biotechnology Companies
  • 11.2. Hospitals & Clinics
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. Live Cell Encapsulation Market, by Cell Type

  • 12.1. Islet Cells
    • 12.1.1. Donor Islet Cells
    • 12.1.2. Stem Cell Derived Islet Cells
  • 12.2. Probiotic Bacteria
    • 12.2.1. Bifidobacterium
    • 12.2.2. Lactobacillus
  • 12.3. Stem Cells
    • 12.3.1. Induced Pluripotent Stem Cells
    • 12.3.2. Mesenchymal Stem Cells

13. Live Cell Encapsulation Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Live Cell Encapsulation Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Live Cell Encapsulation Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AUSTRIANOVA
    • 16.3.2. Merck KGaA
    • 16.3.3. Sphere Fluidics Ltd.
    • 16.3.4. ViaCyte, Inc.
    • 16.3.5. Blacktrace Holdings Ltd. (Dolomite Microfluidics)
    • 16.3.6. BIO INX
    • 16.3.7. Living Cell Technologies Ltd.
    • 16.3.8. Sigilon Therapeutics, Inc.
    • 16.3.9. Isogen
    • 16.3.10. Diatranz Otsuka Ltd.
    • 16.3.11. Sernova Corporation
    • 16.3.12. Atelerix Ltd.
    • 16.3.13. Neurotech Pharmaceuticals
    • 16.3.14. Kadimastem
    • 16.3.15. BUCHI Labortechnik AG
    • 16.3.16. Fluigent
    • 16.3.17. Encapsys LLC
    • 16.3.18. MiKroCaps
    • 16.3.19. Reed Pacific Pty Limited
    • 16.3.20. Lycored

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. LIVE CELL ENCAPSULATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. LIVE CELL ENCAPSULATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVE CELL ENCAPSULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS LIVE CELL ENCAPSUL